Shows
Kidney Cancer UnfilteredCancer Doesn't Know an AgeHost Annamaria Scaccia talks with Katie Coleman and Dr. Pavlos Msaouel as they unpack Katie's stage 4 kidney cancer diagnosis at age 29. Katie shares her feelings of naivety and intimidation when she was first diagnosed, the long journey to trusting her treatment plans, and how she transformed her experience into her book, "Too Young for Cancer." Dr. Msaouel, a world-renown researcher and clinician with special expertise in rare types of kidney cancer, has journeyed with Katie and other patients to reach for better treatments and hope for the future. Hosted on Acast. See acast.com/privacy for more information.2024-11-1954 min
Believe in Progress: an AACR Foundation Podcast034: Fighting Rare Kidney Cancers - Katie Coleman and Dr. Pavlos MsaouelIn this inspirational episode of the Believe in Progress Podcast, host Mitch Stoller, Chief Philanthropic Officer at the American Association for Cancer Research, sits down with Katie Coleman, a software engineer, podcaster, author, and stage 4 kidney cancer survivor, alongside Dr. Pavlos Msaouel, a physician-scientist who specializes in rare kidney cancers. Katie and Dr. Msaouel each share their personal journeys and delve into their pioneering work in the fight against cancer. Katie’s advocacy and Dr. Msaouel’s research highlight the power of collaboration, community, and groundbreaking science in driving progress for patients.Episode Highlights:2024-11-0650 min
The View on GU | with Lalani and WallisEpisode 8: Oncology trial design and statistics with Dr. Pavlos MsaouelJoined by MD Anderson Cancer Center clinician and scientist Dr. Pavlos Msaouel, Dr. Aly-Khan Lalani and Dr. Christopher Wallis discuss trial design and statistics in oncology. What are the nuances to reading KM curves? How useful are forest plots? Our guest and hosts dive into this and more in Episode 8.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers.
Learn more about The View on GU: https://theviewongu.com
2024-05-2735 min
Your Stories: Conquering CancerA Collaborative Approach to an Uncommon Cancer Imagine receiving a cancer diagnosis, only to immediately learn that not only has it spread to other parts of your body, but it’s also incredibly rare for it do so—so rare, in fact, that little to no research exists to inform your treatment. Katie Coleman doesn’t need to imagine this: She’s lived it. In December 2020, at just 29 years old, Katie was diagnosed with metastatic oncocytoma, a type of kidney cancer so rare that fewer than 10 cases have been recorded in history. Consequently, it’s also remained largely understudied, underfunded, and overlooked in cancer research. Luckily, Katie foun...2024-03-1934 min
Medscape InDiscussion: Renal Cell CarcinomaRenal Medullary Carcinoma: The Importance of Early and Accurate Screening, Diagnosis, and TreatmentDrs Sumanta Pal and Pavlos Msaouel discuss the unique pathophysiology of renal medullary carcinoma, treatment options, clinical trials, and the importance of screening and early detection. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984239). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Renal Medullary Carcinoma and Its Association With Sickle Cell Trait: A Case Report and Literature Review https://pubmed.ncbi.nlm.nih.gov/32218668/ Renal Medullary Carcinoma: The...2023-06-0623 min
Heme ReviewThe More Data You Have, The Further You Are From The Truth- Big Data Paradox in MedicineDr Pavlos Msaouel: https://faculty.mdanderson.org/profiles/pavlos_msaouel.html
0:00 Pretext and context MD Anderson Cancer Center
1:42 The Early Experiences That Shaped Dr Msaouel
3:39 The System of Cancer Research In the United States
5:25 FDA Drug Approvals and Special Designations For Oncology
11:09 A trade-off in our current system
12:35 Whoops 😞 I misspoke
14:35 Randomized trials are not supposed to be representative of a population
18:10 Inference for the treatment of Katie Coleman (metastatic oncocytoma)
25:12 It is much more valuable to refute hypotheses than to confirm them
28:05 All Models Are Wrong, But Some Are Useful
30:05 Recasting the Bias-Variance Trade-off as the Patient Relevance-Robustness Tra...2023-05-161h 10
The UromigosEpisode 207: Editorial on COSMIC-313Pavlos Msaouel discusses some of the statistical components of this and other RCC studies.2022-12-0529 min
VJOncology PodcastUpdates in Checkpoint Inhibitors for Kidney CancerThe advent of immune checkpoint inhibitors as a distinct class of immunotherapy has made a large impact within the field of oncology, providing a form of treatment that utilizes the host immune system to target the cancer. Immune checkpoint inhibitors regulate the immune system and prevent autoimmunity, with cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death receptor-1 ligand (PD-L1) being common targets for checkpoint inhibitors. Ipilimumab was the first FDA-approves checkpoint inhibitor and was indicated for patients with melanoma. Pembrolizumab and nivolumab, both PD-1 inhibitors, have been approved for renal cell carcinoma (RCC...2022-08-1215 min
VJOncology PodcastUpdates in checkpoint inhibitors for kidney cancerThe advent of immune checkpoint inhibitors as a distinct class of immunotherapy has made a large impact within the field of oncology, providing a form of treatment that utilizes the host immune system to target the cancer. Immune checkpoint inhibitors regulate the immune system and prevent autoimmunity, with cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death receptor-1 ligand (PD-L1) being common targets for checkpoint inhibitors. Ipilimumab was the first FDA-approves checkpoint inhibitor and was indicated for patients with melanoma. Pembrolizumab and nivolumab, both PD-1 inhibitors, have been approved for renal cell carcinoma (RCC...2022-08-1215 minVJOncology PodcastASCO 2022: Updates in Genitourinary CancerThe American Society of Clinical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.
In this podcast, we hear from some of the leading experts in genitourinary cancer, as they discuss the biggest trials and hot topics from the meeting. For prostate cancer, we hear from Prof. Arun Azad who explains the evolution of standard of care for patients with metastatic hormone-sensitive prostate cancer, Prof. Andrew Armstrong who gives us an update on the ARCHES trial, Dr Anis Hamid...2022-07-0827 minVJOncology PodcastASCO 2022: Updates in Genitourinary CancerThe American Society of Clinical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.
In this podcast, we hear from some of the leading experts in genitourinary cancer, as they discuss the biggest trials and hot topics from the meeting. For prostate cancer, we hear from Prof. Arun Azad who explains the evolution of standard of care for patients with metastatic hormone-sensitive prostate cancer, Prof. Andrew Armstrong who gives us an update on the ARCHES trial, Dr A...2022-07-0827 min
The Sickle Cell PodcastSickle Cell Trait + RMC - A Kidney Cancer (Feat. Dr. Pavlos Msaouel, MD, PhD)Did you think Renal Medullary Carcinoma (RMC – a kidney cancer) was a sickle cell trait complication? Listen and learn more about this rare, but aggressive kidney cancer and what signs, symptoms, and precautions to take to stay on top of this issue and your kidney health. Featuring RMC expert Dr. Pavlos Msaouel
---
Support this podcast: https://podcasters.spotify.com/pod/show/thesicklecellpodcast/support2021-06-021h 28
Your Stories: Conquering CancerNo Stone Unturned | Conquer Cancer, the ASCO FoundationWhen Dr. Nizar Tannir ran out of treatment options for patients with Renal Medullary Carcinoma (RMC), a rare kidney cancer, he left his private practice to research a cure. To take on this uncommon disease, he would need the brightest young researchers and a community of supporters whose commitment to new discoveries is as relentless as his. He found an ally in Conquer Cancer researcher Dr. Pavlos Msaouel. In this episode of Your Stories, the friends and colleagues share the stories of patients who inspire their work and the breakthroughs they've discovered by leaving no stone unturned.2020-03-2709 min